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Abstract
Human cystathionine b-synthase (CBS) catalyzes the first irreversible step in the transsulfuration pathway and commits
homocysteine to the synthesis of cysteine. Mutations in CBS are the most common cause of severe hereditary
hyperhomocysteinemia. A yeast two-hybrid approach to screen for proteins that interact with CBS had previously identified
several components of the sumoylation pathway and resulted in the demonstration that CBS is a substrate for sumoylation.
In this study, we demonstrate that sumoylation of CBS is enhanced in the presence of human polycomb group protein 2
(hPc2), an interacting partner that was identified in the initial yeast two-hybrid screen. When the substrates for CBS,
homocysteine and serine for cystathionine generation and homocysteine and cysteine for H2S generation, are added to the
sumoylation mixture, they inhibit the sumoylation reaction, but only in the absence of hPc2. Similarly, the product of the
CBS reaction, cystathionine, inhibits sumoylation in the absence of hPc2. Sumoylation in turn decreases CBS activity by
,28% in the absence of hPc2 and by 70% in its presence. Based on these results, we conclude that hPc2 serves as a SUMO
E3 ligase for CBS, increasing the efficiency of sumoylation. We also demonstrate that c-cystathionase, the second enzyme in
the transsulfuration pathway is a substrate for sumoylation under in vitro conditions. We speculate that the role of this
modification may be for nuclear localization of the cysteine-generating pathway under conditions where nuclear
glutathione demand is high.
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Introduction
Cystathionine b-synthase (CBS)
1 catalyzes the pyridoxal 59-
phosphate-dependent condensation of serine and homocysteine to
form cystathionine, which represents the first committed step in
the transsulfuration pathway for cysteine synthesis [1,2]. Cysta-
thionine is then converted to cysteine in a reaction catalyzed by c-
cystathionase (CSE). Gene disruption of CSE leads to marked
hypertension and impaired vasorelaxation, confirming the impor-
tance of this enzyme as a source of the gaseous signaling molecule,
H2S, which is formed as a side reaction, presumably from cysteine
[3]. Deficiency of CBS activity is the most common cause of
hereditary hyperhomocysteinemia [4] and over one hundred
patient mutations in CBS have been described [5]. Curiously, a
subset of pathogenic CBS mutations when mimicked in vitro
exhibit no apparent biochemical penalty, and in fact, sometimes
display higher activity than wild-type enzyme [6,7]. This has led us
to suggest the hypothesis that these mutations may disrupt
interactions between CBS and other proteins, which are important
for its cellular functions. In an effort to identify such interacting
partner proteins, a yeast two-hybrid screen was undertaken and
furnished a disproportionate number of proteins related to the
sumoylation pathway including the SUMO (small ubiquitin-like
modifier) conjugation enzyme Ubc9 (ubiquitin-conjugating en-
zyme), the SUMO ligases, PIAS1 (protein inhibitor of activated
STAT1) and PIAS3, the RanGTPase binding protein, RanBP,
and human polycomb group protein 2, hPc2 [8]. Human CBS was
subsequently shown to be a target for sumoylation both in vitro as
well as in vivo [8].
SUMO is a small ubiquitin-related modifier protein, which is
covalently attached to target proteins. The human genome
encodes three functional isozymes of SUMO: SUMO-1, -2 and
-3 that are expressed ubiquitously, whereas the paralog, SUMO-4,
may not be fully processed and exhibits a more restricted tissue
distribution [9,10]. Posttranslational modification by SUMO is
one mechanism for dynamic regulation of target proteins and
elicits diverse effects including subcellular relocalization typically
to the nucleus, changes in protein partner interactions and
modulation of the DNA-binding and/or transactivation activities
of transcription factors [11].
The coordinated activities of SUMO activating, conjugating
and ligating enzymes are required for sumoylation, a process that
has parallels with ubiquitination. The first step in this mechanism
is catalyzed by the E1 ubiquitin-activating heterodimeric enzyme,
Aos1-Uba2, and results in the formation of a thioester bond
between the C-terminal glycine residue in SUMO and a cysteine
residue in Uba2. The next step involves transfer of SUMO to the
active site cysteine residue in the E2 ubiquitin carrier protein,
Ubc9. In the final step, the activated carboxyl group of the
terminal glycine residue in SUMO is transferred to the e-amino
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bond. This step is often facilitated by an E3 ubiquitin-protein
isopeptide ligase but some targets are efficiently sumoylated by E2
alone under in vitro conditions [11].
The mechanism by which E3 ligases enhance the kinetics,
specificity and/or efficiency of Ubc9-mediated sumoylation
remains unclear, and they might be particularly important for
SUMO conjugation to substrate proteins that contain variant
consensus motifs [12]. The canonical SUMO acceptor site
contains a lysine residue in the sequence motif, YKXE/D, in
which Y is a hydrophobic residue and X is any amino acid.
However, lysines in variant or non-canonical sequences can also
be sumoylated [12]. E3 proteins facilitate SUMO ligation either
by binding to substrate proteins or by binding to the E2
conjugation enzyme, Ubc9, and stimulating transfer of SUMO
to the substrate or to another SUMO molecule in case of modifier
chain formation [13]. To date, four groups of E3 ligases have been
identified: the SP-RING ligases, which includes the PIAS family
proteins [14], the nuclear pore protein, Ran BP2 [15], the human
polycomb group member, hPc2 [16] and the histone deacetylase,
HDAC4 [17].
The polycomb group proteins are well-studied epigenetic
regulators of the fly homeotic gene cluster that function as
silencers and help maintain the transcriptional history of target
genes over many cell generations [18]. In mammals, homologs of
these proteins are important for maintaining stem cell pluripotency
and the identity of differentiated cells [19]. hPc2 is a member of
the polycomb repressive complex 1, which is required for stable
maintenance of transcriptional repression [18,20,21,22]. hPc2 and
its relatives are characterized by an N-terminal chromatin
organization modifier (chromo) domain and a C-terminal C-box
[23]. hPc2 functions as a SUMO E3 ligase for at least four target
proteins including the transcriptional co-repressor, CtBP [24], the
transcriptional regulator, SIP1 [25], the homeodomain-interacting
protein kinase 2, HIPK2 [26], and the DNA methyltransferase,
Dnmt3a [27].
In this study, we demonstrate that hPc2 functions as an E3
ligase for human CBS and enhances its sumoylation by SUMO-1.
Sumoylation and catalytic turnover appear to be competitive since
sumoylation is inhibited in the presence of the CBS substrates,
serine and homocysteine that generate cystathionine and homo-
cysteine and cysteine that generate H2S as well as the product,
cystathionine. Substrate and product-induced inhibition of
sumoylation is averted in the presence of hPc2. Conversely,
sumoylation of CBS inhibits its activity, and this effect is enhanced
in the presence of hPc2, which increases the extent of CBS
sumoylation. We also demonstrate that the second enzyme in the
transsulfuration pathway, c-cystathionase (CSE), is a substrate for
sumoylation under in vitro conditions.
Results
Sumoylation of CBS is enhanced by hPc2 under in vitro
conditions
To evaluate whether hPc2 serves as an E3 ligase for sumoylation
of CBS, the SUMO modification reaction was reconstituted in vitro
in the presence or absence of hPc2. Western blot analysis using a
SUMO-1 antibody revealed the presence of two high molecular
mass bands (Figure 1) corresponding to ,80 kDa and ,110 kDa
respectively as seen previously [8]. However, in contrast to the
earlier in vitro sumoylation reactions in which an aliquot of rabbit
reticulocyte lysate was added [8], the current kit-based assay
contained only the purified component proteins and exhibited a
higher efficiency of modification. The presence of catalytic
amounts of hPc2 increased the efficiency of the sumoylation
reaction (Figure 1).
Effect of CBS substrates on sumoylation
To investigate whether the sumoylation of CBS was affected by
the presence of substrates, the in vitro sumoylation assays were
performed in the presence or absence of the substrates,
homocysteine and serine. The presence of either substrate
inhibited the sumoylation reaction and only the 110 kDa band
was visible under these conditions (Figure 2A). The presence of the
allosteric activator, S-adenosylmethionine, had no further effect on
the efficiency of CBS sumoylation (Figure 2B). Substrate-induced
inhibition of sumoylation was avoided by the presence hPc2
(Figure 2C).
We next tested the effect of the product, cystathionine, formed
by the condensation of serine and homocysteine, on sumoylation
of CBS. Again, sumoylation was completely inhibited in the
presence of 10 mM cystathionine and this inhibition was alleviated
by the presence of hPC2 (Figure 3). Similarly, the substrates for
H2S generation by CBS, homocysteine and cysteine [28], inhibit
sumoylation but only in the absence of hPc2 (Figure 3). We note
that the total intensity is consistently higher in lanes showing CBS
Figure 1. Effect of hPc2 on sumoylation of human CBS. A. The in
vitro sumoylation reaction was performed as described under Methods
and SUMO-1 antibody was used to detect the presence of sumoylated
CBS. Lanes 1 and 2 show sumoylation reactions that were conducted in
the absence (lane 1) and presence (lane 2) of hPc2. B and C. Equal
loading controls for CBS in the two reaction mixtures. The CBS
concentration prior to the start of the sumoylation reaction was
identical in both lanes as detected by Coomassie blue staining (B) or by
Western blot analysis using CBS antibody (C).
doi:10.1371/journal.pone.0004032.g001
Sumoylation of CBS and CSE
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CBS (Figure 2) antibody is employed for detection, despite equal
loading of CBS in each lane (Figure 1B,C). The basis for this is not
understood.
Effect of sumoylation on CBS activity
The effect of sumoylation on CBS activity was assessed
following a 6 h sumoylation reaction in the presence or absence
of hPc2. As controls, the activity of CBS incubated for the same
duration but in the absence of the sumoylating agents or in the
presence of only hPc2 was determined. In comparison to the
controls, sumoylation resulted in the loss of 28% and 70% of CBS
activity in the absence and presence respectively, of hPc2. We note
that CBS exists in a mixed oligomeric state ranging from a dimer
to higher order oligomers [29]. In the in vitro assay, CBS subunits
are hypersumoylated resulting in a mixture of unsumoylated
subunits and those with 1 or more SUMO modifications
(Figure 2A and B, lane 2 and Figure 2C, lanes 2 and 4). Hence,
although the efficiency of CBS monomer sumoylation in the in
vitro assay is low (20–50%), the extent of inhibition exceeds the
level of sumoylation suggesting that modification of some of the
subunits interferes with the activity of the native protein.
In vitro sumoylation of CSE
While the significance of nuclear localization of CBS is not
known, it is pertinent to ask if the next enzyme in the pathway,
CSE, is subjected to sumoylation and therefore also has the
potential to relocate to the nucleus under some conditions. As a
first step towards addressing this question, we have examined
whether recombinant human CSE can be sumoylated. Under in
vitro conditions, we observe sumoylation of CSE and the
appearance of two major bands with molecular masses of ,65
and 85 kDa versus 45 kDa for the parent CSE subunit. The
presence of 5 mM cystathionine, the substrate for CSE, did not
affect the efficiency of the sumoylation reaction.
Discussion
In mammals, the transsulfuration pathway plays important roles
in clearing homocysteine, in methionine homeostasis, and in
providing cysteine especially in cells that exhibit a high turnover of
the antioxidant, glutathione. CBS is a heavily regulated enzyme at
the homocysteine metabolic junction and defects in CBS result in
severely elevated homocysteine levels and multiorgan deficits,
whose molecular basis is poorly understood. A yeast two-hybrid
analysis conducted in our laboratory identified a number of
proteins involved in the sumoylation pathway as potential
interacting partners of CBS including a number of E3 ligases
e.g. PIAS1, PIAS3 and hPc2 [8]. It was speculated that the
multiplicity of E3 ligases identified by the yeast two-hybrid
approach could have been a consequence of complex formation
between the E3 prey and the endogenous yeast E2, which in turn
interacted with the CBS bait. The PIAS proteins are members of
the largest family of E3 ligases whereas hPc2 has a much more
limited range of substrates possibly because of its nuclear
Figure 2. Effect of substrates on the sumoylation of human
CBS. Western blot analysis using CBS-antibody of sumoylation reaction
mixtures containing the substrates for CBS in the absence (A) or
presence (B) of the allosteric activator, S-adenosylmethionine (AdoMet).
(C) The effect of hPc2 on sumoylation of human CBS in the presence of
substrates.
doi:10.1371/journal.pone.0004032.g002
Figure 3. Effect of the H2S generating substrates, cysteine and
homocysteine, and the CBS reaction product, cystathionine, on
sumoylation in the presence and absence of hPc2. The Western
blot was detected using SUMO-1 antibody.
doi:10.1371/journal.pone.0004032.g003
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examined the effect of hPc2 on the efficiency of CBS sumoylation.
Both SUMO-2 and SUMO-3 have internal consensus SUMO
modification sites that allow polymerization on target proteins
[13,31]. In contrast, an internal sumoylation site is absent in
SUMO-1 and ligation of only monomeric units is observed with
this modifier. Since SUMO-1 was used in the assay mixtures, the
observation of multiple bands corresponding to sumoylated CBS
in the vitro assay (Figure 1A), which has also been reported
previously [8], and to CSE (Figure 4) suggests that sumoylation
occurred at more than one site. Although SUMO is an ,11 kDa
protein, modification of the target proteins typically results in an
,20–30 kDa band shift [32]. The subunit molecular mass of
human CBS is 63 kDa and the 80 kDa band appears to be
associated with sumoylation at K211, which resides within a
canonical sumoylation site. Mutation of K211 to arginine leads to
loss of the 80 kDa band [8]. Human CBS has a variant
sumoylation site, LK269EK, in which the acidic residue found in
the consensus motif is missing. K269 like K211, is relatively
surface exposed in the structure of the truncated CBS dimer
(Figure 5A). Human CSE has at least three lysine residues in
potential sumoylation motifs of which one, LK361ND, is in a
consensus sequence whereas two, LK330NL and LK260TL, are
present in what appear to be variant sequences. Of these, K260
seems unlikely to be a sumoylation site based on the crystal
structure as it is buried in the subunit interface while the other two
lysines are relatively surface exposed (Figure 5B). Examples of
sumoylation at variant sites have been reported, and while it is not
known how Ubc9 recognizes such target sequences, it is speculated
that the E3 component may be especially influential in
modifications involving variant sites [12,33]. We note however,
that the SUMO hypermodification of CBS that is observed in the
in vitro assay is not seen in vivo where only the 80 kDa modified
band is seen [8].
In the absence of hPc2, sumoylation and substrate binding to
CBS appear to be competitive. Hence, the presence of either
serine or homocysteine, cysteine and homocysteine or the product,
cystathionine, results in a markedly reduced efficiency of SUMO
modification (Figures 2 and 3). This suggests that substrate binding
induces a conformational change that reduces the efficiency of
interaction between Ubc9 and CBS. While the KM for
homocysteine (5 mM [34]) and cysteine (6 mM [28]) are high
compared to the intracellular concentrations of homocysteine and
cysteine in mammalian cells, which is in the 10–100 mM range,
the intracellular concentration of serine is significantly higher
(,560 mM) [28] while the KD for serine for human CBS is low
(7.5 mM [35]). This suggests that in the cytoplasm, sumoylation of
CBS may be largely inhibited under most circumstances.
Although the majority of SUMO targets are nuclear proteins, a
growing number of non-nuclear targets in the cytoplasm, plasma
membrane and mitochondria have been identified [9]. Sumoyla-
tion of CBS could trigger its nuclear localization. Enhanced
sumoylation of CBS in the presence of hPc2 might be expected to
occur in the nucleus since hPc2 has a restricted subnuclear
localization within polycomb bodies. We note however that initial
nuclear localization studies on CBS have revealed its presence in
the nuclear scaffold [8]. We also note that most SUMO targets do
not exhibit quantitative modification. Rather, a small proportion
of the target protein tends to be modified and low-level
sumoylation can have significant cellular effects as described for
transcription factors and for thymine DNA glycosylase [9].
The significance of SUMO modification of CBS is not known
nor is the role of this protein in the nuclear compartment.
Figure 4. Human CSE is a target of in vitro sumoylation.
Sumoylation of CSE was conducted as described under Methods in the
presence or absence of 5 mM cystathionine. The Western blot was
detected using SUMO antibody. The band with a molecular mass of
,16 kDa represents SUMO-1 present in the reaction mixture.
doi:10.1371/journal.pone.0004032.g004
Figure 5. Structures of human CBS and CSE showing locations of potential SUMO modification sites. A. Locations of K211 and K269 in
the canonical and noncanonical SUMO modification sites respectively in human CBS (PDB 1M54). The two subunits of CBS are shown in grey and blue
and the heme and PLP cofactors are shown in red and yellow respectively. K211 and K269 are shown in one of the two subunits in navy and cyan
respectively. B. Locations of K361 (blue), K330 (cyan) and K260 (red) in one of the four subunits of human CSE (PDB file 2NMP). The PLP cofactor is
shown in yellow in ball and stick representation.
doi:10.1371/journal.pone.0004032.g005
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and whether some proportion of this enzyme is found in the
nucleus. One possibility is that the nuclear CBS moonlights in an
altogether different role, which remains to be identified. An
alternative is that sumoylation leads both enzymes of the
transsulfuration pathway into the nucleus where they function
locally in the removal of homocysteine, in the provision of cysteine
and/or H2S, a gaseous signaling molecule. Of these, cysteine
production may be the most significant since this amino acid is the
limiting reagent in the synthesis of glutathione. The nuclear:cy-
toplasmic ratio of glutathione varies from ,1 to 4 depending on
the cell cycle stage and the nuclear pool peaks just prior to
exponential cell growth [36]. It is estimated that between 4 to 8
percent of glutathione synthesis occurs in the nucleus and activities
for the biosynthetic enzymes, c-glutamyl cysteine ligase and
glutathione synthetase, have been reported in this compartment
[37]. Peak telomerase activity is correlated with high nuclear
glutathione levels [38], and it is believed that a reducing
environment might be important for the optimal functioning of
other nuclear proteins. CBS activity also varies with the stage of
cell-growth with maximal expression occurring during cell
proliferation [39]. Hence, nuclear localization of the transsulfura-
tion pathway enzymes, CBS and CSE, might be a strategy for
ensuring local delivery of cysteine under conditions of high
glutathione demand in the nucleus.
A potential problem with this model for SUMO-dependent
translocation of the transsulfuration pathway enzymes is that
sumoylation of CBS is associated with inhibition of its activity
(Table 1). Hence, if sumoylation is required to bring CBS (and
potentially, CSE) into the nucleus, desumoylation of nuclear CBS
would be needed for the enzyme to be active. We note that
SUMO modification is dynamic and the modified targets can be
rapidly desumoylated by isopeptidases that are efficient at
removing SUMO. CBS is a long-lived protein with a half life
that is estimated to be ,49 h [40]. Hence, once it is translocated
into the nucleus and desumoylated, it could potentially function as
a catalyst in this compartment for some time.
It is interesting to note that a component of the well-studied
cytoplasmic folate cycle has been demonstrated to have a nuclear
localization that is dependent on SUMO modification [41].
Cytoplasmic serine hydroxymethyltransferase is a target of SUMO
modification both in vivo and in vitro and has been shown to also
have a nuclear residence. The two other enzymes needed for de
novo thymidylate synthesis, dihydrofolate reductase and thymi-
dylate synthase, also contain SUMO modification consensus
sequences and sumoylation might underlie the nuclear localization
of this part of the folate-dependent one-carbon pathway for local
synthesis of the DNA precursor, thymidylate [41].
In summary, we have demonstrated that both enzymes in the
transsulfuration pathway, CBS and c-cystathionase, are targets of
in vitro sumoylation and that hPc2 functions as an E3 ligase for
CBS. It is not known if the physiological relevance of this
modification is to relocate some proportion of the transsulfuration
pathway into the nucleus for local production of cysteine needed
for glutathione synthesis under cellular conditions or if these
proteins serve a different function in the nuclear compartment.
Materials and Methods
Materials
The following materials were purchased from Sigma: D,L-
homocysteine, L-cysteine, serine and cystathionine. Glutathione S-
transferase was purchased from GE Healthcare. ECL anti-rabbit
IgG horseradish peroxidase-linked whole antibody (from donkey),
ECL anti-mouse IgG, horseradish peroxidase-linked whole anti-
body (from sheep) and [
14C]-serine (specific activity=1.64 mCi/
mmol (50 mCi/vial)) were purchased from GE Healthcare. Aos1/
Uba2, Ubc9, SUMO-1 and SUMO-1 rabbit monoclonal antibody
were purchased with the SUMOlink kit from Active Motif,
Carlsbad, CA. Chicken polyclonal CBS antibody, previously
generated in our laboratory, was used for CBS Western blot
analyses. Horseradish peroxidase-labeled goat anti-chicken IgY was
purchased from Aves Labs, Oregon. Detection of horseradish
peroxidase conjugated secondary antibodies was performed using
the supersignal chemiluminescent substrate purchased from Pierce
Biotechnology, IL. Protease Inhibitor tablets were purchased from
Roche Diagnostics, Indianapolis, IN, USA.
CBS, CSE and hPc2 Protein Expression and Purification
Recombinant human CSE was purified as described previously
[42]. Recombinant human CBS was expressed and purified using
the parent plasmids pGEX4-T1/hCBS, which produces a fusion
protein with glutathionine S-transferase at the N-terminus, as
described previously [43] with the exception that the initial anion
exchange chromatography step was omitted. E. coli BL21 (DE3)
cells were transformed with the expression vector for human hPc2
(pHis-Parallel1 encoding amino acids 2–529), which was a
generous gift from Dr. David Wotton (University of Virginia).
Transformed BL21 (DE3) was grown in Luria Bertaini medium at
37uC till the OD600 reached 0.6. IPTG (isopropyl b-D-1-
thiogalactopyranoside) was added to a final concentration of
5 mM and the culture was grown for an additional 12 h at 18uC.
The cells were harvested by centrifugation at 60006g for 30 min
and washed with lysis buffer (50 mM sodium phosphate, pH 8.0,
300 mM NaCl and 10% v/v glycerol) and resuspended in 100 ml
of lysis buffer supplemented with 10 mM 2-mercaptoethanol,
1 mg/ml leupeptin and 1 mM PMSF. The cells were disrupted by
sonication and the extract was centrifuged at 16,0006g for
30 min. The supernatant was loaded onto a Ni-NTA column
(863 cm) pre-equilibrated with lysis buffer and washed with the
lysis buffer supplemented with 10 mM 2-mercaptoethanol and
20 mM imidazole. The column was eluted with a gradient ranging
from 20–250 mM imidazole in lysis buffer containing containing
10 mM 2-mercaptoethanol. Approximately 3 mg of hPc2 was
obtained per liter of culture by this method and was stored at
280uC until further use.
In vitro sumoylation of CBS and CSE
Sumoylation reactions were performed using the commercially
available SUMOlink kit as follows. Aos1/Uba2, Ubc9 (2 ml each)
Table 1. Sumoylation inhibits CBS activity.
Additions
a
Pre-incubation
time
Activity
mmol h
21 mg
21
Percent activity
remaining
b
CBS none 286636
CBS 6 h 157621 100
CBS+hPc2 6 h 180611 100
CBS+SUMO-1
a 6h 1 2 1 625 72
CBS+SUMO-1+hPc2
a 6h 5 0 613 30
aIn vitro sumoylation of CBS was performed as described under Methods.
bThe activity remaining after 6 h of incubation needed for the sumoylation
reaction is reported relative to the average of the CBS and CBS+hPc2 assay
mixtures (169 mmol h
21 mg
21).
doi:10.1371/journal.pone.0004032.t001
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human CBS (8 pmol) or recombinant human CSE (12 pmol) in
the presence or absence of purified hPc2 (2 pmol) in the
commercially supplied sumoylation buffer to a final volume of
22.5 ml. When the effect of CBS substrates on the efficiency of
sumoylation was examined, the reaction mixture contained one or
more of the following additions: 0.38 mM AdoMet, 30 mM L-
serine, 15 mM DL-homocysteine, 10 mM cystathionine, 10 mM
cysteine. When the effect of substrate on the efficiency of CSE
sumoylation was tested, 5 mM cystathionine was added. The
reaction mixture was incubated for 6 h at 37uC and quenched
with an equal volume of 56SDS loading buffer (250 mM Tris HCl
pH 6.8, 10% SDS, 30% glycerol, 5% b-mercaptoethanol, 0.02%
bromophenol blue) followed by incubation at 95uC for 10 min.
Each experiment was performed at least in triplicate.
Western blot analysis
To identify the presence of SUMO-modified CBS or CSE, the
reaction mixtures were separated on a 12% polyacrylamide gel
under denaturing conditions. The gels were transferred to
polyvinylidene fluoride microporous membranes (Biorad, Hercu-
les, CA) at room temperature for 4 h at 350 mA using a Transblot
apparatus (BioRad). After blocking, the membranes were probed
with polyclonal CBS antibody(1:2000 dilution) or monoclonal
SUMO-1 antibody (1:4000 dilution). The recombinant hPc2 used
in these studies contains an N–terminal His tag and was detected
with an anti-His tag antibody (1:3000 dilution). CBS and SUMO-
1 Western blots were detected with horseradish peroxidase-labeled
goat anti chicken antibody (1:50,000 dilution for CBS) and ECL
anti-rabbit IgG horseradish peroxidase-linked whole antibody
from donkey (1: 50,000 dilution for SUMO-1) respectively.
Western blots for hPc2 were detected with mouse IgG horseradish
peroxidase-linked whole antibody from sheep (1:50,000 dilution).
The membranes were visualized using the super signal chemilu-
minescent substrate.
Effect of sumoylation on CBS activity
CBS activity was measured in the radiolabeled assay described
previously [43]. To test the effect of sumoylation on activity, CBS
(1 mg) was sumoylated as described above except that the amount
of CBS and SUMO-1 in the assay mixture were doubled (to
16 pmole of CBS subunits and 20 pmol of SUMO-1) and
incubated for 6 h at 37uC. At the end of this incubation, 5 mlo f
each reaction mixture was removed and quenched with an equal
volume of SDS loading buffer as described above and to the
remaining volume, the following assay components were added in
a final volume of 200 ml: 250 mM Tris HCl, pH 8.6, 0.25 mM
PLP, 0.38 mM AdoMet, 30 mM [
14C]-serine (,50,000 dpm/
mmol), and the sumoylated mixture and incubated for 5 min at
37uC. The CBS reaction was started with 30 mM D,L-
homocysteine, incubated at 37uC for 60 min and terminated with
200 ml of 10% trifluoroacetic acid. The mixture was centrifuged
for 10 min at 11,0006g to remove any precipitate and the sample
was processed as described previously [43].
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